ID
42476
Descrição
Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. Please note that only cases with known outcome are collected! Baseline / diagnosis is defined as the day the sample of the first positive SARS-CoV-2 result was taken. Criteria of the Uncomplicated Phase: Asymptomatic OR Symptoms of upper respiratory tract infection and/or Nausea, emesis, diarrhea and/or Fever Remember: The Uncomplicated Phase ends, if a previously febrile patient has no fever anymore and has completed 14 days of follow-up without entering Complicated or Critical Phase; then move to Recovery Phase. Also, as soon as one of the criteria of the Complicated or Critical Phase are fulfilled, Uncomplicated Phase ends; move over to there. If the patient has died, the phase ends with the death of the patient. If the patient has died, do not report terminal values, e.g. those recorded after switching off life-support or heart rate "0" after death of the patient. Criteria of the Complicated Phase: * Need for oxygen supplementation (In patients with prior oxygen home therapy, clinically meaningful increase in need for oxygenation.) * paO2 at room air < 70 mmHg * SO2 at room air < 90 % * GOT or GPT > 5x ULN * New cardiac arrhythmia * New pericardial effusion >1cm * New heart failure with pulmonary edema, congestive hepatopathy or peripheral edema Remember: The Complicated Phase ends, if none of the criteria for the Complicated Phase is fulfilled anymore AND the patient is free of fever; then move to Recovery Phase. Also, as soon as one of the criteria of the Critical Phase are fulfilled, Complicated Phase ends; move over to Critical Phase. If the patient has died, the phase ends with the death of the patient. If the patient has died, do not report terminal values, e.g. those recorded after switching off life-support or heart rate "0" after death of the patient. Criteria of the Critical Phase: * Need for catecholamines * Life-threatening cardiac arrhythmia * Mechanical ventilation (invasive or non-invasive) * Liver failure with Quick< 50% * qSOFA >= 2 * Renal failure in need of dialysis Remember: The Critical Phase ends as soon as none of the criteria for the Critical Phase is fulfilled anymore AND the patient is free of fever. If the patient has died, it ends with the death of the patient. If the patient has died, do not report terminal values, i.e. those recorded after turning off life-support or heart rate "0" after death of the patient. Criteria of the Recovery Phase: *Improvement by at least one phase, i.e. Critical to Complicated or Complicated to Uncomplicated * Defervescence Remember: Uncomplicated asymptomatic patients enter recovery phase after 14 days of observation without disease progression No further progression or re-hospitalization If a text field can't be filled out, note 'ND' (for not determined).
Link
Palavras-chave
Versões (3)
- 02/07/2021 02/07/2021 - Sarah Riepenhausen
- 15/07/2021 15/07/2021 - Sarah Riepenhausen
- 16/07/2021 16/07/2021 - Sarah Riepenhausen
Titular dos direitos
LEOSS
Transferido a
16 de julho de 2021
DOI
10.21961/mdm:42476
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients
Immunosuppressive premedication
- StudyEvent: Baseline
- StudyEvent: Comorbidities and Pre-medication
- StudyEvent: Phases
- StudyEvent: Therapeutics
- StudyEvent: Diagnostics
Descrição
Antibodies: CD-22
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C0054947
Descrição
Antibodies: CD-38
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C0075742
Descrição
Antibodies: CD-52
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C1610534
Descrição
Antibodies: Anti-CD79b
Alias
- UMLS CUI-1
- C0104979
- UMLS CUI-2
- C0003241
Descrição
Antibodies: B Lymphocyte stimulator-specific inhibitor (BLyS)
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C3160093
Descrição
Antibodies: CD19-BiTE
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C4727095
Descrição
Antibodies: Complement inhibitors
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C1564892
Descrição
Crovalimab
Tipo de dados
integer
Alias
- UMLS CUI [1,1]
- C1564892
- UMLS CUI [1,2]
- C3846158
Descrição
Eculizumab
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C1541483
Descrição
Pegcetacoplan (APL-2)
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C4053680
Descrição
Ravulizumab
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C4550350
Descrição
Antibodies: Integrin antagonists
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C2917367
Descrição
Antibodies: Interleukin inhibitors
Alias
- UMLS CUI-1
- C3653320
- UMLS CUI-2
- C0003241
Descrição
Basiliximab
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C0676831
Descrição
Canakinumab
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C2718773
Descrição
Ixekizumab
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C3489764
Descrição
Sarilumab
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C3885145
Descrição
Secukinumab
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C3179547
Descrição
Tocilizumab
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C1609165
Descrição
Ustekinumab
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C1608841
Descrição
Antibodies: TNF-alpha inhibitors
Alias
- UMLS CUI-1
- C3653350
- UMLS CUI-2
- C0003241
Descrição
Adalimumab
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C1122087
Descrição
Certolizumab
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C1872109
Descrição
Etanercept
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C0717758
Descrição
Golimumab
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C2353893
Descrição
Infliximab
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C0666743
Descrição
Other Antibodies
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C0205394
Descrição
Inhibitors: Co-stimulation inhibitors
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C1622572
- UMLS CUI-3
- C1999216
Descrição
Inhibitors: Calcineurin inhibitors
Alias
- UMLS CUI-1
- C1562036
Descrição
Inhibitors: Interleukin inhibitor
Alias
- UMLS CUI-1
- C3653320
Descrição
Inhibitors: JAK inhibitors
Alias
- UMLS CUI-1
- C3854325
Descrição
Baricitinib
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C4044947
Descrição
Fedratinib
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C3886623
Descrição
Ruxolitinib
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C2931926
Descrição
Tofacitinib
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C2930696
Descrição
Upadacitinib
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C4726929
Descrição
Inhibitors: mTOR inhibitors
Alias
- UMLS CUI-1
- C2746052
Descrição
Inhibitor: PDE-4-inhibitor
Alias
- UMLS CUI-1
- C2936609
Descrição
Other Inhibitors
Alias
- UMLS CUI-1
- C0205394
- UMLS CUI-2
- C0243077
Descrição
Checkpoint inhibitors: last 3 months
Alias
- UMLS CUI-1
- C0332185
- UMLS CUI-2
- C4733472
Descrição
In case of combination therapy please indicate all of the respective drugs.
Tipo de dados
boolean
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C3657270
Descrição
In case of combination therapy please indicate all of the respective drugs.
Tipo de dados
boolean
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C3658706
Descrição
In case of combination therapy please indicate all of the respective drugs.
Tipo de dados
boolean
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C1367202
Descrição
In case of combination therapy please indicate all of the respective drugs.
Tipo de dados
boolean
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C0205394
- UMLS CUI [1,3]
- C4733472
Descrição
Indicate recent other checkpoint inhibitor
Tipo de dados
text
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C0205394
- UMLS CUI [1,3]
- C4733472
- UMLS CUI [1,4]
- C1521902
Descrição
No recent checkpoint inhibitor therapy
Tipo de dados
boolean
Alias
- UMLS CUI [1,1]
- C1298908
- UMLS CUI [1,2]
- C0332185
- UMLS CUI [1,3]
- C4733472
Descrição
Unknown Checkpoint inhibitor therapy
Tipo de dados
boolean
Alias
- UMLS CUI [1,1]
- C0439673
- UMLS CUI [1,2]
- C0332185
- UMLS CUI [1,3]
- C4733472
Descrição
Chemotherapeutics: Antimetabolites
Alias
- UMLS CUI-1
- C0003376
- UMLS CUI-2
- C0729502
Descrição
6-Mercaptopurine
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C0000618
Descrição
Azathioprine
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C0004482
Descrição
Leflunomide
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C0063041
Descrição
Methotrexate
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C0025677
Descrição
Mycophenolate mofetil / Mycophenolic acid
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C0209368
- UMLS CUI [2]
- C0026933
Descrição
Sulfasalazine
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C0036078
Descrição
Teriflunomide
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C1718383
Descrição
Chemotherapeutics: Cytostatics
Alias
- UMLS CUI-1
- C0010858
- UMLS CUI-2
- C0729502
Descrição
Recent: Cladribine (2-CDA) i.v./s.c.
Tipo de dados
integer
Alias
- UMLS CUI [1,1]
- C0092801
- UMLS CUI [1,2]
- C0348016
- UMLS CUI [1,3]
- C0332185
- UMLS CUI [2,1]
- C0092801
- UMLS CUI [2,2]
- C0021499
- UMLS CUI [2,3]
- C0332185
Descrição
Recent: Cladribine (2-CDA) p.o.
Tipo de dados
integer
Alias
- UMLS CUI [1,1]
- C0092801
- UMLS CUI [1,2]
- C0001563
- UMLS CUI [1,3]
- C0332185
Descrição
Recent: Cyclophosphamide i.v.
Tipo de dados
integer
Alias
- UMLS CUI [1,1]
- C0010583
- UMLS CUI [1,2]
- C0348016
- UMLS CUI [1,3]
- C0332185
Descrição
Recent: Cyclophosphamide p.o.
Tipo de dados
integer
Alias
- UMLS CUI [1,1]
- C0010583
- UMLS CUI [1,2]
- C0001563
- UMLS CUI [1,3]
- C0332185
Descrição
Recent: Mitoxantrone
Tipo de dados
integer
Alias
- UMLS CUI [1,1]
- C0026259
- UMLS CUI [1,2]
- C0332185
Descrição
Other Chemotherapeutics
Alias
- UMLS CUI-1
- C0205394
- UMLS CUI-2
- C0729502
Descrição
Other Chemotherapeutics
Tipo de dados
integer
Alias
- UMLS CUI [1,1]
- C0205394
- UMLS CUI [1,2]
- C0729502
Descrição
Indicate other Chemotherapeutics
Tipo de dados
text
Alias
- UMLS CUI [1,1]
- C0729502
- UMLS CUI [1,2]
- C0205394
- UMLS CUI [1,3]
- C1521902
Descrição
Other immunosuppressive regimens: Corticosteroids
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C0001617
Descrição
low dose prednisolone equivalent
Tipo de dados
integer
Alias
- UMLS CUI [1,1]
- C0445550
- UMLS CUI [1,2]
- C0038317
Descrição
medium dose prednisolone equivalent
Tipo de dados
integer
Alias
- UMLS CUI [1,1]
- C0439536
- UMLS CUI [1,2]
- C0178602
- UMLS CUI [1,3]
- C0038317
Descrição
high dose prednisolone equivalent
Tipo de dados
integer
Alias
- UMLS CUI [1,1]
- C0038317
- UMLS CUI [1,2]
- C0444956
Descrição
Other immunosuppressive regimens: Fumarate
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C0220833
Descrição
Dimethyl fumarate
Tipo de dados
integer
Alias
- UMLS CUI [1]
- C0058218
Descrição
Dimethyl fumarate/ethyl hydrogen fumarate (Fumaderm)
Tipo de dados
integer
Alias
- UMLS CUI [1,1]
- C0058218
- UMLS CUI [1,2]
- C0059764
- UMLS CUI [2]
- C0633802
Descrição
Other immunosuppressive regimens: Immunoglobulines
Alias
- UMLS CUI-1
- C1963758
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C0021081
Descrição
Other immunosuppressive regimens: Interferon
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C3652465
Descrição
Other immunosuppressive regimens: Other Multiple Sclerosis drugs
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C0013227
- UMLS CUI-4
- C0026769
Descrição
Other immunosuppressive regimens
Alias
- UMLS CUI-1
- C0205394
- UMLS CUI-2
- C0021081
Descrição
Other immunosuppressive drugs
Tipo de dados
integer
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C0205394
Descrição
Indicate other immunosuppressive drugs
Tipo de dados
text
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C0205394
- UMLS CUI [1,3]
- C1521902
Descrição
Immunosuppressive drugs: Underlying disease
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C3146298
Descrição
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Tipo de dados
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0026769
Descrição
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Tipo de dados
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0205494
- UMLS CUI [1,4]
- C0004364
- UMLS CUI [1,5]
- C0205394
Descrição
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Tipo de dados
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0205478
Descrição
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Tipo de dados
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0029216
Descrição
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Tipo de dados
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C3495832
Descrição
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Tipo de dados
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0277554
- UMLS CUI [1,4]
- C0205394
Descrição
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Tipo de dados
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0277554
- UMLS CUI [1,4]
- C0205394
- UMLS CUI [1,5]
- C1521902
Descrição
Indication for immunosuppressive drugs: Unknown underlying disease
Tipo de dados
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0439673
- UMLS CUI [1,4]
- C0277554
Descrição
Is data entry for this section finished?
Alias
- UMLS CUI-1
- C4684556
- UMLS CUI-2
- C1828479
- UMLS CUI-3
- C0205197
Similar models
Immunosuppressive premedication
- StudyEvent: Baseline
- StudyEvent: Comorbidities and Pre-medication
- StudyEvent: Phases
- StudyEvent: Therapeutics
- StudyEvent: Diagnostics
C0332185 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,2])
C0003241 (UMLS CUI-2)
C3160093 (UMLS CUI-2)
C0332185 (UMLS CUI [1,2])
C1564892 (UMLS CUI-2)
C2917367 (UMLS CUI-2)
C0003241 (UMLS CUI-2)
C0003241 (UMLS CUI-2)
C1521902 (UMLS CUI [1,2])
C0003241 (UMLS CUI [1,3])
C1622572 (UMLS CUI-2)
C1999216 (UMLS CUI-3)
C1521902 (UMLS CUI [1,2])
C0243077 (UMLS CUI [1,3])
C4733472 (UMLS CUI-2)
C3657270 (UMLS CUI [1,2])
C3658706 (UMLS CUI [1,2])
C1367202 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])
C4733472 (UMLS CUI [1,3])
C0205394 (UMLS CUI [1,2])
C4733472 (UMLS CUI [1,3])
C1521902 (UMLS CUI [1,4])
C0332185 (UMLS CUI [1,2])
C4733472 (UMLS CUI [1,3])
C0332185 (UMLS CUI [1,2])
C4733472 (UMLS CUI [1,3])
C0729502 (UMLS CUI-2)
C0026933 (UMLS CUI [2])
C0729502 (UMLS CUI-2)
C0348016 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0092801 (UMLS CUI [2,1])
C0021499 (UMLS CUI [2,2])
C0332185 (UMLS CUI [2,3])
C0001563 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0348016 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0001563 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0332185 (UMLS CUI [1,2])
C0729502 (UMLS CUI-2)
C0729502 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])
C1521902 (UMLS CUI [1,3])
C0205394 (UMLS CUI-2)
C0001617 (UMLS CUI-3)
C0038317 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,2])
C0038317 (UMLS CUI [1,3])
C0444956 (UMLS CUI [1,2])
C0205394 (UMLS CUI-2)
C0220833 (UMLS CUI-3)
C0059764 (UMLS CUI [1,2])
C0633802 (UMLS CUI [2])
C0205394 (UMLS CUI-2)
C0021081 (UMLS CUI-3)
C0348016 (UMLS CUI [1,2])
C0021499 (UMLS CUI [1,2])
C0205394 (UMLS CUI-2)
C3652465 (UMLS CUI-3)
C0205394 (UMLS CUI-2)
C0013227 (UMLS CUI-3)
C0026769 (UMLS CUI-4)
C0021081 (UMLS CUI-2)
C0205394 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])
C1521902 (UMLS CUI [1,3])
C3146298 (UMLS CUI-2)
C3146298 (UMLS CUI [1,2])
C0026769 (UMLS CUI [1,3])
C3146298 (UMLS CUI [1,2])
C0205494 (UMLS CUI [1,3])
C0004364 (UMLS CUI [1,4])
C0205394 (UMLS CUI [1,5])
C3146298 (UMLS CUI [1,2])
C0205478 (UMLS CUI [1,3])
C3146298 (UMLS CUI [1,2])
C0029216 (UMLS CUI [1,3])
C3146298 (UMLS CUI [1,2])
C3495832 (UMLS CUI [1,3])
C3146298 (UMLS CUI [1,2])
C0277554 (UMLS CUI [1,3])
C0205394 (UMLS CUI [1,4])
C3146298 (UMLS CUI [1,2])
C0277554 (UMLS CUI [1,3])
C0205394 (UMLS CUI [1,4])
C1521902 (UMLS CUI [1,5])
C3146298 (UMLS CUI [1,2])
C0439673 (UMLS CUI [1,3])
C0277554 (UMLS CUI [1,4])
C1828479 (UMLS CUI-2)
C0205197 (UMLS CUI-3)
C1828479 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])